Fox Business - The Power to Prosper
Search Site

Eli Lilly

Corrections happen, but fundamentals still matter

Chase Bank Chief Economist Anthony Chan says even though corrections occur investors should focus on improving fundamentals.

Read More

  1. Eli Lilly CEO talks pipeline growth

    Eli Lilly CEO John Lechleiter gives his outlook for growth and new products.

  2. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  3. The health-care stocks to boost your portfolio

    Rehmann Financial Principal Joe Heider on the health-care stocks to watch.

  4. Biotechs with big goals, but no office space or full-time employees?

    Alkeus Pharmaceuticals CEO Leonide Saad on the company’s research.

  5. The next golden age of M&A

    Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.

  6. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  7. Lilly Sales Below Views, Trims Profit Forecast

    U.S. drugmaker Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs.Lilly said i...

  8. Pharma Deal Frenzy: A Bid to Boost Profits

    High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...

  9. Amgen Slumps After 1Q Earnings Miss

    Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...

  10. Novartis focusing on three giant areas

    Novartis CEO Joe Jimenez on his company’s corporate transformation and focus on pharmaceuticals, eyecare and generics.

  11. U.S. futures look for direction

    FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.

  12. Novartis Announces Multi-Billion-Dollar Revamp

    Novartis (NYSE:NVS) is revamping its portfolio with a flurry of deals worth about $25 billion, as the Swiss pharmaceutical giant plans to swap assets with GlaxoSmith...

  1. Eli Lilly CEO: We hope to resume growth next year

    Eli Lilly CEO John Lechleiter discusses his outlook for growth and when he expects to have patent expirations behind.

  2. Eli Lilly posts 3Q earnings miss

    Earnings HQ: FBN’s Lori Rothman breaks down Eli Lilly ’s third-quarter earnings report.

  3. Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

    Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

  4. Eli Lilly 2Q earnings beat expectations

    Earnings HQ: FBN’s Ashley Webster breaks down Eli Lilly ’s second-quarter earnings report.

  5. Spending on pets surges

    Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.

  6. Eli Lilly CEO on cancer: We’re in store for further advances

    Eli Lilly CEO John Lechleiter on where we are in the fight for cancer.

  7. How to bring cash back to America

    Schulte, Roth & Zabel managing partner Paul Roth weighs in on the U.S. corporate tax rate.

‹ Prev12345Next ›
Freebase CC-BY
Source: Eli Lilly on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL